A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy.

MLA

Ferro, Matteo, et al. “A Risk-Group Classification Model in Patients with Bladder Cancer under Neoadjuvant Cisplatin-Based Combination Chemotherapy.” Future Oncology (London, England), vol. 17, no. 30, Oct. 2021, pp. 3987–94. EBSCOhost, https://doi.org/10.2217/fon-2020-1298.

APA

Ferro, M., Lucarelli, G., de Cobelli, O., Dolce, P., Terracciano, D., Musi, G., Porreca, A., Busetto, G. M., Del Giudice, F., Soria, F., Gontero, P., Cantiello, F., Damiano, R., Crocerossa, F., Abu Farhan, A. R., Autorino, R., Vartolomei, M. D., Marchioni, M., Mari, A., … Buonerba, C. (2021). A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. Future Oncology (London, England), 17(30), 3987–3994. https://doi.org/10.2217/fon-2020-1298

Chicago

Ferro, Matteo, Giuseppe Lucarelli, Ottavio de Cobelli, Pasquale Dolce, Daniela Terracciano, Gennaro Musi, Angelo Porreca, et al. 2021. “A Risk-Group Classification Model in Patients with Bladder Cancer under Neoadjuvant Cisplatin-Based Combination Chemotherapy.” Future Oncology (London, England) 17 (30): 3987–94. doi:10.2217/fon-2020-1298.